The global erythropoietin (EPO) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the global erythropoietin market includes rise in prevalence of anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART). Hence, rise in number of treatment cycles for chemotherapy and rising incidences of end stage renal diseases (dialysis) has increased the demand for EPO drugs. Side effects associated with EPO including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) restrain growth of the erythropoietin drugs market. Moreover, rise in trends of commercialization of EPO biosimilars, readily available reimbursements, favorable government regulations, and increase in level of awareness regarding benefits of EPO therapeutics are some factors that are expected to fuel the growth of the erythropoietin drugs market during the forecast period. EPO/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused by end stage renal disease (ESRD) disease treatments and dialysis procedures. Followed by ESRD anemic condition, EPO drugs have gained approvals for chemotherapy-induced anemia.  

After post-abbreviated new drug application (ANDA) approvals and high success rate of EPO applications for chemotherapy-induced anemia, biopharmaceutical companies turned their attention to another form of induced anemia, namely ART-induced anemia (among HIV patients). Currently, scientists are planning a randomized clinical trial to systematically investigate effects of treating COVID-19 using erythropoietin. It is a hormone/cytokine produced mainly by kidneys via hypoxia inducible factor-2 as its primary transcription factor and through inhibition of apoptosis of RBC precursors. However, EPO has other beneficial cytoprotective effects including anti-ischemic, regenerative, and anti-apoptotic effects in a variety of tissues including lung, kidney, cardiac muscle, nervous system, retina, pancreas, and endothelial cells. Through a special receptor; EPOR-?cR, it conducts its protective effects following trauma in critically ill patients. Thus, impact of COVID-19 pandemic is expected to remain positive for key players in the global erythropoietin market.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Class

o By Product Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Amgen Inc., Johnson & Johnson Services, Inc., and F. Hoffman La-Roche AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Erythropoietin Market Report by Segment

By Drug Class 

• Biologics
• Biosimilars

By Product Type

• Epoetin-Alfa
• Epoetin-Beta
• Darbepoetin-Alfa
• Others

By Application

• Hematology
• Cancer
• Kidney Disorder
• Others

Global Erythropoietin Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa